Although fewer antibody fragments have entered the clinic than full-length monoclonal antibodies, proof-of-concept studies for these therapeutics remain the main hurdle. Tufts Center for the Study ...

Here, we discuss strategies to select the best therapeutic antigen targets, to optimize the structure of IgG antibodies and to design related or new structures with additional functions.

These findings in the human are at the basis of our proposed structure-function model in which the antigen binding features of the germline template antibody are dictated by the somatically ...

Certolizumab pegol is distinct from other TNFi in terms of its structure. It is composed of the antibody binding fragment (Fab) of humanized monoclonal antibody against TNF conjugated to ...